Digital Diagnostics, formerly IDx, a developer of AI-powered medical diagnostic tools for various eye conditions, raised a $75M Series B led by KKR
Context & Ripple Effects
Digital Diagnostics' $75M Series B closes a four-year arc that began with its $33M Series A as IDx back in 2018, and it lands in a suddenly crowded lane: Heru pulled in $30M for AR/VR-headset-based vision diagnostics, and Eyenuk followed months later with a $26M round for diabetic-retinopathy screening.
The lead investor is the real signal here. KKR — which per related reporting has secured over $10B for its Helix Digital Infrastructure vehicle to build AI data centers — is simultaneously buying into the application layer of clinical AI, treating diagnostics software as part of the same capital deployment thesis rather than a separate bet.
First-order effects
- Digital Diagnostics now holds more than twice the capital of its 2018 Series A, giving it PE-scale resources to push its autonomous eye-diagnosis platform from FDA-cleared novelty into routine primary-care screening.
- KKR adds a clinical-AI operating company to a portfolio otherwise weighted toward infrastructure, hedging its AI exposure across both the compute layer and the revenue-generating application layer.
Second-order effects
- Eyenuk and Heru now compete against a rival whose lead investor can write nine-figure follow-on checks without syndicating — their next rounds likely get sized up, and strategic acquirers gain a price anchor for the whole eye-screening category.
- With sources reporting KKR and peers have turned down some data-center debt over insufficient insurance coverage against natural-disaster risk, applied-AI assets like diagnostic software offer large funds a deployment target without that specific collateral problem.
Third-order effects
- If buyout-scale funds keep leading clinical-AI rounds rather than waiting for growth-stage entry, the diagnostics sector consolidates around companies that can finance regulatory clearance and distribution simultaneously — structurally disadvantaging sub-$50M-funded startups regardless of technical merit.
- The pattern points toward a two-tier AI market where the same institutions own the data centers and the applications running on them, raising familiar questions about circular financing between affiliated layers of the stack.
The trend: Institutional capital is moving down the AI stack from infrastructure into applied clinical AI, with ophthalmic screening emerging as the first category to attract buyout-scale checks.